Expense for Development is Justified
The first Russian generic pramipexole (INN pramipexole) for Parkinson disease has been approved.
The Ministry of Industry and Trade of the Russian Federation is the originator of the drug, which is included into the Vital and Essential Drug List.
Development of the first Russian generic drug pramipexole within the Federal Target Program “Pharma-202” was sponsored out of the federal budget at 16 mln rubles. The market size, according to the INN data almost 30-fold exceeds expenses for generic development. Last year the market size was 448.01 mln Russian rubles.
Therefore, expenses for development of new import substitution products are well-justified.